JPMorgan initiates Spyre stock with Overweight on IBD pipeline

JPMorgan has initiated coverage on Spyre Therapeutics Inc. (NASDAQ:SYRE) with an Overweight rating and a price target of $110.00, following the biotech company's remarkable 441% gain over the past year. Spyre is developing six clinical-stage assets for inflammatory bowel disease (IBD), including three monotherapies targeting α4β7, TL1A, and IL-23.

Analyst Hardik Parikh believes that the company's combination therapies could differentiate them from competitors by providing convenience and less frequent dosing. JPMorgan projects that Spyre can capture a low-teens percentage share of the U.S. advanced biologics IBD market by the 2040s, resulting in annual worldwide sales of $6 billion to $7 billion.

Despite the company's strong liquidity and lack of profitability this year, analysts do not expect profitability this year, which is typical for clinical-stage biotech firms.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.